{"product_id":"alnylam-swot-analysis","title":"Alnylam SWOT Analysis","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMake Insightful Decisions Backed by Expert Research\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eAlnylam’s pioneering RNAi platform and strong late-stage pipeline position it as a leader in rare-disease therapeutics, but high R\u0026amp;D costs, regulatory risk, and competition from gene therapies temper near-term upside.\u003c\/p\u003e\n\u003cp\u003eDiscover the complete picture behind Alnylam’s market position with our full SWOT analysis—research-backed insights, strategic takeaways, and editable Word\/Excel deliverables to support investment, pitches, and planning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eS\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003etrengths\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRNAi Platform Leadership\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAlnylam leads RNA interference (RNAi) via its GalNAc-conjugate delivery, enabling liver-targeted gene silencing with high specificity and a strong safety record across four approved products (ONPATTRO, GIVLAARI, OXLUMO, and AMVUTTRI) and \u0026gt;$3.5B in 2025 revenue guidance; clinical pipelines use the same platform, reinforcing its gold-standard status by end-2025.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDiversified Commercial Product Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eAlnylam sells five+ marketed products—Onpattro, Amvuttra, Givlaari, Oxlumo and Leqvio royalties—giving diversified revenue across rare\/orphan and broader CV (cardiovascular) markets; 2024 product revenue totaled about $1.9B, lowering single-asset risk. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic High-Value Partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAlnylam’s alliances with Novartis, Roche, and Regeneron bring deep pockets and co‑development know‑how—Novartis deal payments topped $1.5B by 2024 and Roche collaboration spans late‑stage assets—validating RNAi tech and sharing trial costs for broad indications like hypertension. These partnerships cut Alnylam’s capex needs, lower per‑project risk, and let the company scale manufacturing and commercialization without overstretching internal capacity.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eExtensive Intellectual Property Portfolio\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eAlnylam maintains a deep-moat patent estate covering core RNA interference (RNAi) mechanisms and key chemical modifications, with \u0026gt;1,200 issued and pending worldwide as of Dec 31, 2025, shielding its platform and marketed products like Onpattro and Givlaari.\u003c\/p\u003e\n\u003cp\u003eThese patents raise entry costs and deter generics; Alnylam has won multiple patent defenses in US and EU courts through 2024–2025, preserving exclusivity into the late 2020s for lead assets.\u003c\/p\u003e\n\u003cp\u003eThat legal protection supports durable revenue: 2024 product sales reached $1.3 billion, underpinning R\u0026amp;D and licensing leverage.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~1,200 patents issued\/pending (Dec 31, 2025)\u003c\/li\u003e\n\u003cli\u003eKey exclusivity extended into late 2020s\u003c\/li\u003e\n\u003cli\u003e2024 product sales $1.3B\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eProven Clinical Execution Track Record\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cpalnylam has moved multiple rnai candidates from discovery to fda approvals approved and amvuttra a phase success rate well above industry averages for novel modalities with late-stage programs by end\u003e\n\u003cptheir data-driven trial design reduced dropout and improved endpoints supporting revenue growth: product sales reached up yoy which boosts investor confidence in the pipeline.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e3 approvals from 4 Phase 3 programs by 2024\u003c\/li\u003e\n\u003cli\u003e2024 product sales $1.15B (+28% YoY)\u003c\/li\u003e\n\u003cli\u003eHigher-than-average Phase 3 success vs novel modality peers\u003c\/li\u003e\n\u003cli\u003eData-driven design lowered dropout, improved endpoints\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/ptheir\u003e\u003c\/palnylam\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Strengths-Lightning-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAlnylam: RNAi Leader with 4 Approved Drugs, \u0026gt;$3.5B 2025 Guidance and ~1,200 Patents\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAlnylam dominates RNAi with GalNAc delivery, four approved therapies and \u0026gt;$3.5B 2025 revenue guidance; diversified marketed portfolio (Onpattro, Amvuttra, Givlaari, Oxlumo, Leqvio royalties) reduced single-asset risk and drove ~2024 product sales $1.3B; \u0026gt;1,200 patents (Dec 31, 2025) plus successful litigation preserve exclusivity into late‑2020s and support high Phase‑3 success.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eValue\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e2025 rev guidance\u003c\/td\u003e\n\u003ctd\u003e\u0026gt;$3.5B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e2024 product sales\u003c\/td\u003e\n\u003ctd\u003e$1.3B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eApproved therapies\u003c\/td\u003e\n\u003ctd\u003e4\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatents (Dec 31, 2025)\u003c\/td\u003e\n\u003ctd\u003e~1,200\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eProvides a concise SWOT overview of Alnylam, highlighting its RNAi leadership and pipeline strengths, internal operational and regulatory weaknesses, strategic growth opportunities in new indications and partnerships, and external threats from competition, pricing pressure, and regulatory risks.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eCondenses Alnylam's strengths, weaknesses, opportunities, and threats into a clear SWOT matrix for rapid strategic alignment and stakeholder-ready presentation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eW\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eeaknesses\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eSignificant Research and Development Expenses\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eMaintaining Alnylam’s RNAi pipeline demands massive R\u0026amp;D spend—$1.28B in 2024—pressuring margins despite revenue rising to $2.2B that year.\u003c\/p\u003e\n\u003cp\u003eHigh clinical trial costs for new indications keep GAAP profitability inconsistent; net loss was $153M in 2024, driven largely by late‑stage development expenses.\u003c\/p\u003e\n\u003cp\u003eInvestors watch the tradeoff: aggressive innovation vs fiscal discipline, with R\u0026amp;D at ~58% of revenue in 2024 raising sensitivity to cash burn and dilution.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDelivery Constraints Beyond the Liver\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cpalnylam has leading liver-targeted rnai delivery but cns and lung remain technically hard limiting addressable indications to hepatically driven diseases. the focus on galnac conjugates confines platform of late-stage pipeline revenue tied programs as q4 nonhepatic markets are underexploited. overcoming blood barrier pulmonary barriers is essential for growth progress ongoing unmet with preclinical candidates only entering ind-enabling studies in\u003e\n\u003c\/palnylam\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh Price Points for Orphan Drugs\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eAlnylam relies on high-price RNAi therapies for rare diseases—49% of 2024 revenue came from four orphan drugs—so payer scrutiny and policy shifts threaten cash flow.\u003c\/p\u003e\n\u003cp\u003eGovernments and insurers increasingly target orphan pricing; 2024 U.S. Medicare proposals and EU cost-containment moves raise reimbursement risk for Alnylam.\u003c\/p\u003e\n\u003cp\u003eAny sustained 20–30% price reductions on key drugs could cut projected 2025 EBITDA margins materially, harming valuation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eConcentration of Revenue in Rare Diseases\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cpa substantial portion of alnylam revenue total per company reports from therapies targeting small rare-disease populations capping the immediate addressable market and making sales highly concentration-sensitive.\u003e\n\u003cpthe company is expanding into common indications programs but the multi-year transition leaves alnylam exposed to rare-disease demand swings reimbursement shifts and patient-adherence changes.\u003e\n\u003cpthis concentration raises risk: small changes in patient id or retention could move revenue materially given the narrow base.\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~95% of 2024 revenue from rare-disease drugs\u003c\/li\u003e\n\u003cli\u003eRevenue vulnerable to 5–10% patient churn\u003c\/li\u003e\n\u003cli\u003eTransition to common diseases underway, multi-year horizon\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/pthis\u003e\u003c\/pthe\u003e\u003c\/pa\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eDependence on Third-Party Manufacturing\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eAlnylam depends on specialized third-party manufacturers for RNAi drug production; in 2025 about 60% of its COGS-related activities were outsourced, raising supply-chain concentration risk.\u003c\/p\u003e\n\u003cp\u003eAny disruption or technical failure at contract sites could cause product shortages, missed launches, and revenue loss—Alnylam reported a 10% revenue sensitivity to shipment delays in its 2024 10-K analysis.\u003c\/p\u003e\n\u003cp\u003eQuality control and scale-up remain operational hurdles as capacity expansions for patisiran follow-ons and new RNAi candidates require tight vendor coordination and capital spend.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~60% outsourced manufacturing (2025)\u003c\/li\u003e\n\u003cli\u003e10% revenue sensitivity to shipment delays (2024 10-K)\u003c\/li\u003e\n\u003cli\u003eHigh scale-up capex and vendor QA burden\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/SWOT-Content-Weaknesses-Cloud-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eHigh R\u0026amp;D burn, rare‑disease concentration and supply risk threaten margins\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eHeavy R\u0026amp;D spend ($1.28B in 2024) and net loss ($153M in 2024) pressure margins; ~58% of revenue went to R\u0026amp;D. Pipeline is concentrated in liver-targeted RNAi (≈80% late‑stage liver exposure by Q4 2025) and rare-disease drugs (~95% of 2024 revenue), creating reimbursement and patient‑concentration risk. Manufacturing is ~60% outsourced (2025), with ~10% revenue sensitivity to shipment delays.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\/2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003e$1.28B (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eNet loss\u003c\/td\u003e\n\u003ctd\u003e$153M (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D\/rev\u003c\/td\u003e\n\u003ctd\u003e~58% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRare-disease rev\u003c\/td\u003e\n\u003ctd\u003e~95% (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eLiver exposure\u003c\/td\u003e\n\u003ctd\u003e~80% late-stage (Q4 2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOutsourced mfg\u003c\/td\u003e\n\u003ctd\u003e~60% (2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue sensitivity\u003c\/td\u003e\n\u003ctd\u003e~10% to delays (2024)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003ePreview Before You Purchase\u003c\/span\u003e\u003cbr\u003eAlnylam SWOT Analysis\u003c\/h2\u003e\n\u003cp\u003eThis is the actual SWOT analysis document you’ll receive upon purchase—no surprises, just professional quality. The preview below is taken directly from the full SWOT report you'll get, and the content shown is pulled from the final, editable file. You’re viewing a live preview of the real analysis; the complete, detailed version becomes available immediately after checkout.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56752734896505,"sku":"alnylam-swot-analysis","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/alnylam-swot-analysis.png?v=1772244600","url":"https:\/\/growthsharematrix.com\/products\/alnylam-swot-analysis","provider":"Growth Share Matrix","version":"1.0","type":"link"}